In Vitro Diagnostics Business Outlook, Volume 3, Issue 6 - Focus on Glucose Testing Overview
(price includes 6 issues published every two months)In Vitro Diagnostics Business Outlook is a bimonthly publication with six issues annually.
In Vitro Diagnostics Business Outlook offers information and data that you cannot get anywhere else, including:
Market data and forecasts (growth rates, market size, market share, etc.) to identify growth opportunities
- A comprehensive view of the IVD market with test categories covered and company briefs
- M&A activities, selected partnerships & collaborations, partnership deals, and more
- Industry & region watch to help tailor strategies
- Analysis of news and events and reporting on news not easily available
- MARKET ANALYSIS: IVD GLUCOSE TESTING
- OVERVIEW OF IVD GLUCOSE TESTING
- MARKET OUTLOOK
- Table: Global Diabetes Sales, by Test Category, 2024-2029 ($ million) (Glucose OTC; Glucose Professional; Glucose, Continuous; HbA1c POC; HbA1c Lab)
- Figure: Global Diabetes Testing Market, by Segment with CAGR 2024-2029 ($ million) (Glucose OTC; Glucose Professional; Glucose, Continuous; HbA1c POC; HbA1c Lab)
- REGIONAL MARKET
- Figure: Global Diabetes Prevalence, 20-79y, 2021 Estimates (per 1,000s)
- Figure: Global Distribution, Diabetes Test Market, 2024 (%) (Glucose, HbA1c)
- COMPANY BRIEFS
- Abbott Diagnostics
- Dexcom
- Roche
- EXECUTIVE NEWS BRIEFING
- BRIEFS
- Agilent Reorganizes Business Units
- Natera Co-Founder Named R&D Leader of the Year
- QIAGEN Moves QIAstat-Dx to Drive Growth
- OraSure Receives Funding
- AmplifiDx Captures Additional Funding
- 52North Closes $6 Million in Funding
- FINANCIAL HIGHLIGHTS: ABBOTT LABORATORIES, QIAGEN
- ABBOTT CONTINUES STEADY PERFORMANCE IN 2024; 9M SALES INCREASE 3.7%
- Figure: Abbott Sales by Business, 9M 2023 and 9M 2024 ($ million)
- Table: Diagnostic Sales, Abbott Laboratories, 9M 2023 and 2024 ($ million)
- Figure: Diagnostic Sales, Abbott Laboratories, 9M 2023 and 2024 ($ million)
- Table: COVID-19 Test Sales, Abbott Laboratories, 9M 2023 and 2024 ($ million)
- Figure: Diabetes Care, Abbott Laboratories, 9M 2023 and 9M 2024 ($ million)
- QIAGEN REPORTS STRONG PERFORMANCE IN Q3 2024; RAISES GUIDANCE
- Figure: QIAGEN Revenue Mix by Business Segment, 9M 2024 ($ million) (Molecular Diagnostics, Life Sciences)
- Figure: QIAGEN Sales by Product Group, 9M 2024 ($ million) (Sample Technologies, Diagnostic Solutions, PCR/Nucleic Acid Amplification, Genomics/NGS, Other)
- Table: QIAGEN Sales, by Product Type, 9M 2023 and 9M 2024 ($ million) (CAGR %) (Consumables and Related Revenues, Instruments)
- Figure: QIAGEN Diagnostic Solutions Sales, by Segment, 9M 2023 and 9M 2024 ($ million) (QuantiFERON, QIAstat-Dx, NeuMoDx, Other)
- Figure: QIAGEN Sales, by Geographic Region, 9M 2023 and 9M 2024 ($ million) (Americas, EMEA, Asia Pacific/Japan)
- DIAGNOSTIC MARKET MERGERS, ACQUISITIONS AND PARTNERSHIP DEALS
- PARTNERSHIPS AND COLLABORATIONS
- MERGERS AND ACQUISITIONS
- Table: Recent Diagnostic Market Mergers, Acquisitions and Partnership Deals, Dec. 2023-Nov. 2024
- INDUSTRY WATCH
- INDUSTRY WATCH COVID-19/FLU UPDATE
- REGION WATCH
- VIETNAM
- Figure: Vietnam GDP, Composition by Sector, 2023 (%) (Agriculture, Forestry, Fishery; Industry, Construction; Services)
- Figure: Vietnam GDP Value and Growth by Year, 2015-2023 ($ billion)
- BROAD-BASED COMPANY ANNOUNCEMENTS
- ANNOUNCEMENTS
- Roche Receives FDA Expanded Approval
- Foundation Medicine Received FDA Companion Diagnostic Approval
- Deepull Receives FDA Breakthrough Device Designation
- bioMérieux Snags Clearance for Tropical Fever Panel
- Roche Receives CE Mark for New Cobas Systems 2.0
- Agilent Received Certification for Companion Diagnostic
Research Assistance
Download our eBook: How to Succeed Using Market Research
Learn how to effectively navigate the market research process to help guide your organization on the journey to success.
Download eBook